Draft Guidance for Industry on Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention; Availability, 11420 [E8-3974]
Download as PDF
11420
Federal Register / Vol. 73, No. 42 / Monday, March 3, 2008 / Notices
and the number of requests, it may be
necessary to limit the time of each presenter.
Contact Person for More Information:
Claudine Johnson, Clerk, Lead Poisoning
Prevention Branch, Division of
Environmental Emergency Health Services,
National Center for Environmental Health,
CDC, 4770 Buford Hwy., NE., Mailstop F–60,
Atlanta, GA 30341, Telephone: (770) 488–
3629, Fax (770) 488–3635.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: February 27, 2008.
Diane Allen,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E8–4085 Filed 2–29–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–D–0118]
Draft Guidance for Industry on
Diabetes Mellitus: Developing Drugs
and Therapeutic Biologics for
Treatment and Prevention; Availability
AGENCY:
Food and Drug Administration,
HHS.
rmajette on PROD1PC64 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry entitled ‘‘Diabetes Mellitus:
Developing Drugs and Therapeutic
Biologics for Treatment and
Prevention.’’ The draft guidance
provides recommendations for industry
for developing drugs and therapeutic
biologics for the prevention and
treatment of diabetes mellitus. Because
diabetes mellitus has reached epidemic
proportions in the United States, FDA
recognizes the need for new products
that can be used as part of a
comprehensive treatment strategy in the
treatment and prevention of diabetes. In
addition to the draft guidance, FDA
plans to convene a public advisory
committee meeting to specifically
discuss new approaches for the
development of products for the
treatment of diabetes, with particular
emphasis on the design and
implementation of studies to assess
long-term cardiovascular risks and
benefits of these new products. FDA
plans to announce the meeting date in
a future issue of the Federal Register.
VerDate Aug<31>2005
15:33 Feb 29, 2008
Jkt 214001
Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
written or electronic comments on the
draft guidance by May 2, 2008.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857. Send one selfaddressed adhesive label to assist that
office in processing your requests.
Submit written comments on the draft
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance
document.
FOR FURTHER INFORMATION CONTACT: Ilan
Irony, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 22, rm. 3100, Silver Spring,
MD 20993–0002, 301–796–2290.
SUPPLEMENTARY INFORMATION:
DATES:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Diabetes Mellitus: Developing Drugs
and Therapeutic Biologics for Treatment
and Prevention.’’ Although a number of
drugs are available for the treatment of
type 1 and type 2 diabetes, many
patients remain inadequately controlled,
and thus are exposed to a higher risk of
long-term complications. This draft
guidance provides recommendations on
the following topics related to the
treatment of type 1 and type 2 diabetes
mellitus:
• Diabetes-specific preclinical
studies;
• Different study designs in different
phases of drug development for both
type 1 and type 2 diabetes;
• Study endpoints in the assessment
of pharmacokinetic/pharmacodynamic
profiles and for efficacy and safety
assessment in treating patients with
diabetes;
• Study population considerations in
different phases of development;
• Sample sizes;
• Study duration; and
• Specific statistical issues related to
development of drugs and biologics
intended for the treatment of diabetes.
The draft guidance also provides
recommendations regarding the
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
development of products for the
prevention of both type 1 and type 2
diabetes.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the agency’s current thinking
on the treatment and prevention of
diabetes mellitus. It does not create or
confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Please note that on January 15, 2008,
the FDA Web site transitioned to the
Federal Dockets Management System
(FDMS). FDMS is a Government-wide,
electronic docket management system.
Electronic submissions will be accepted
by FDA through FDMS only.
III. Electronic Access
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/cder/guidance/
index.htm or https://www.fda.gov/
ohrms/dockets/default.htm.
Dated: February 25, 2008.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E8–3974 Filed 2–29–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Organ Procurement and
Transplantation Network
Health Resources and Services
Administration (HRSA), HHS.
ACTION: Request for information.
AGENCY:
SUMMARY: HRSA, Healthcare Systems
Bureau, Division of Transplantation
(DoT) is in the process of information-
E:\FR\FM\03MRN1.SGM
03MRN1
Agencies
[Federal Register Volume 73, Number 42 (Monday, March 3, 2008)]
[Notices]
[Page 11420]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-3974]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-D-0118]
Draft Guidance for Industry on Diabetes Mellitus: Developing
Drugs and Therapeutic Biologics for Treatment and Prevention;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance for industry entitled ``Diabetes
Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and
Prevention.'' The draft guidance provides recommendations for industry
for developing drugs and therapeutic biologics for the prevention and
treatment of diabetes mellitus. Because diabetes mellitus has reached
epidemic proportions in the United States, FDA recognizes the need for
new products that can be used as part of a comprehensive treatment
strategy in the treatment and prevention of diabetes. In addition to
the draft guidance, FDA plans to convene a public advisory committee
meeting to specifically discuss new approaches for the development of
products for the treatment of diabetes, with particular emphasis on the
design and implementation of studies to assess long-term cardiovascular
risks and benefits of these new products. FDA plans to announce the
meeting date in a future issue of the Federal Register.
DATES: Although you can comment on any guidance at any time (see 21
CFR 10.115(g)(5)), to ensure that the agency considers your comment on
this draft guidance before it begins work on the final version of the
guidance, submit written or electronic comments on the draft guidance
by May 2, 2008.
ADDRESSES: Submit written requests for single copies of the draft
guidance to the Division of Drug Information (HFD-240), Center for Drug
Evaluation and Research, Food and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857. Send one self-addressed adhesive label to
assist that office in processing your requests. Submit written comments
on the draft guidance to the Division of Dockets Management (HFA-305),
Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Submit electronic comments to https://www.regulations.gov. See
the SUPPLEMENTARY INFORMATION section for electronic access to the
draft guidance document.
FOR FURTHER INFORMATION CONTACT: Ilan Irony, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 22, rm. 3100, Silver Spring, MD 20993-0002, 301-796-2290.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a draft guidance for industry
entitled ``Diabetes Mellitus: Developing Drugs and Therapeutic
Biologics for Treatment and Prevention.'' Although a number of drugs
are available for the treatment of type 1 and type 2 diabetes, many
patients remain inadequately controlled, and thus are exposed to a
higher risk of long-term complications. This draft guidance provides
recommendations on the following topics related to the treatment of
type 1 and type 2 diabetes mellitus:
Diabetes-specific preclinical studies;
Different study designs in different phases of drug
development for both type 1 and type 2 diabetes;
Study endpoints in the assessment of pharmacokinetic/
pharmacodynamic profiles and for efficacy and safety assessment in
treating patients with diabetes;
Study population considerations in different phases of
development;
Sample sizes;
Study duration; and
Specific statistical issues related to development of
drugs and biologics intended for the treatment of diabetes.
The draft guidance also provides recommendations regarding the
development of products for the prevention of both type 1 and type 2
diabetes.
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the agency's current thinking on the
treatment and prevention of diabetes mellitus. It does not create or
confer any rights for or on any person and does not operate to bind FDA
or the public. An alternative approach may be used if such approach
satisfies the requirements of the applicable statutes and regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. Received comments may be seen in the
Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
Please note that on January 15, 2008, the FDA Web site transitioned
to the Federal Dockets Management System (FDMS). FDMS is a Government-
wide, electronic docket management system. Electronic submissions will
be accepted by FDA through FDMS only.
III. Electronic Access
Persons with access to the Internet may obtain the document at
either https://www.fda.gov/cder/guidance/index.htm or https://
www.fda.gov/ohrms/dockets/default.htm.
Dated: February 25, 2008.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E8-3974 Filed 2-29-08; 8:45 am]
BILLING CODE 4160-01-S